Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J
The 2024 Standards of Care in Diabetes does emphasize use of certain GLP-1 medications over others for certain goals
Cagrilintide is a newer long-acting amylin analogue - in a phase 2 trial, once weekly cagrilintide resulted in a dose-dependent WL between 6 and 10.8% compared to 9% with liraglutide 3 mg and 3% with placebo [87]
Again, the range reflects two different assumptions about how long anti-obesity medications prevent diabetes (four years or over a lifetime)
GLP-1 is one of the hormones responsible for the incretin effect, and exerts a wide variety of actions such as potentiation of glucose-stimulated insulin secretion, reduction of appetite, delay of gastric emptying and inhibit cell dysfunction (Rondas et al., 2013)
Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, et al